National and Kapodistrian University of Athens
Μελέτη της αποτελεσματικότητας των καρβαπενεμών εναντίον κλινικού στελέχους που παράγει μέταλλο-β-λακταμάση σε πειραματικό μοντέλο ενδοπεριτοναϊκού αποστήματος
Abstract
dc:descriptionAlthough metallo-b-lactamases (MBLs) hydrolyze most b-lactams including carbapenems, MBL-producing Enterobacteriaceae very often remain susceptible to carbapenems in vitro. Given this, we studied the in vivo efficacy of imipenem, meropenem, ertapenem and aztreonam against a carbapenem-susceptible MBL-producing clinical Escherichia coli strain in a rabbit intra-abdominal abscess model.Methods: Rabbits were inoculated intraperitoneally with 108 cfu/ml of VIM-1-positive E. coli and were assigned to receive no treatment (controls) or intravenous 1) imipenem/cilastatin (imipenem) 70 mg/kg/12h 30 min infusion or 2) meropenem 125 mg/kg/12h 10 min infusion or 3) ertapenem 60 mg/kg/12h bolus or 4) aztreonam 70 mg/kg/12h bolus. Dosing regimens were chosen on the basis of preliminary pharmacokinetic studies, so that T>MIC was achieved for ≥50% of the dosing interval for all tested antibiotics. A total of eight doses were administered before sacrifice and the abscesses were harvested and quantitatively cultured.Results: MICs of imipenem, meropenem, ertapenem and aztreonam for the infecting isolate were 1, ≤0.25, 1.5 and ≤0.25 mg/L, respectively. The log10 cfu/g (mean±SD) of viable counts in pus was as follows: controls (n=16), 8.71±1.34 (P<0.001 versus all other groups); imipenem (n=15), 4.89±2.42; meropenem (n=15), 4.24±2.44; ertapenem (n=16), 3.17±1.85 (P=0.022 versus imipenem); and aztreonam (n=15), 3.62±3.05. Mortality among treated rabbits was significantly reduced compared with controls. Four animals in the aztreonam group (26.7%) had culture-negative pus and no mortality was noted among aztreonam-treated animals. Conclusions: In the rabbit experimental model carbapenems were shown to be effective in the treatment of intra-abdominal infection due to an extended-spectrum b-lactamase-negative carbapenem-susceptible VIM-1-producing clinical E. coli strain, but treatment with aztreonam resulted in a more favourable outcome overall.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Konstantinidou, Eleftheria
- Κωνσταντινίδου, Ελευθερία
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41349